NAV

Prostalene

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Prostalene
DrugBank Accession Number
DB11454
Background

Analog of prostaglandin F2 alpha.

Type
Small Molecule
Groups
Vet approved
Structure
Similar Structures
Weight
Average: 380.525
Monoisotopic: 380.256274259
Chemical Formula
C22H36O5
Synonyms
  • Prostalene
  • Prostaleno
External IDs
  • RS-9390
  • RS9390
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AceclofenacThe therapeutic efficacy of Prostalene can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Prostalene can be decreased when used in combination with Acemetacin.
Acetylsalicylic acidThe therapeutic efficacy of Prostalene can be decreased when used in combination with Acetylsalicylic acid.
AlclofenacThe therapeutic efficacy of Prostalene can be decreased when used in combination with Alclofenac.
AminophenazoneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Aminophenazone.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Synchrocept

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as fatty acid methyl esters. These are compounds containing a fatty acid that is esterified with a methyl group. They have the general structure RC(=O)OR', where R=fatty aliphatic tail or organyl group and R'=methyl group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acid esters
Direct Parent
Fatty acid methyl esters
Alternative Parents
Cyclopentanols / Tertiary alcohols / Methyl esters / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alcohol / Aliphatic homomonocyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic alcohol / Cyclopentanol / Fatty acid methyl ester / Hydrocarbon derivative / Methyl ester
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
O02SWY8981
CAS number
54120-61-5
InChI Key
GNIYHUSSKSFYBD-MFZPGRHISA-N
InChI
InChI=1S/C22H36O5/c1-4-5-10-14-22(2,26)15-13-18-17(19(23)16-20(18)24)11-8-6-7-9-12-21(25)27-3/h7-8,13,15,17-20,23-24,26H,4-5,9-12,14,16H2,1-3H3/b15-13+/t6?,17-,18-,19+,20-,22-/m1/s1
IUPAC Name
methyl 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl]hepta-4,5-dienoate
SMILES
CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=C=CCCC(=O)OC

References

General References
  1. Ley WB, Purswell BJ, Bowen JM: The effects of prostalene and alfaprostol as uterine myotonics, and the effect on postpartum pregnancy rate in the mare following daily treatment with prostalene. Theriogenology. 1988;29(5):1113-21. [Article]
  2. Averkin G, Schiltz R: Summary of the effect of prostalene, a new synthetic prostaglandin, on the breeding efficiency of mares. Vet Med Small Anim Clin. 1976 Nov;71(11):1616, 1621-3. [Article]
  3. Vickery BH, McRae GI, Bajka A: Luteolysis and termination of early pregnancy in the rhesus monkey with prostalene, a synthetic prostaglandin analog. Prostaglandins Med. 1979 Mar;2(3):191-201. [Article]
  4. Bosu WT, McKinnon AO: Induction of abortion during midgestation in mares. Can Vet J. 1982 Dec;23(12):358-60. [Article]
  5. Hamm D, Witherspoon DM, Buell JR, Chen CL, Jochle W: Determination of clinical and luteolytic effectiveness of a prostaglandin analog in mares by a dose response study. Theriogenology. 1981 Oct;16(4):447-57. [Article]
  6. Loy RG, Buell JR, Stevenson W, Hamm D: Sources of variation in response intervals after prostaglandin treatment in mares with functional corpora lutea. J Reprod Fertil Suppl. 1979;(27):229-35. [Article]
  7. Imel KJ, Squires EL, Elsden RP, Shideler RK: Collection and transfer of equine embryos. J Am Vet Med Assoc. 1981 Nov 15;179(10):987-91. [Article]
  8. Vickery B, Briones W, Holstein A: Opposite and mutually antagonistic effects on uterine contractility of two epimeric forms of a synthetic prostaglandin analog. Prostaglandins Med. 1979 Jan;2(1):3-10. [Article]
KEGG Drug
D05642
ChemSpider
4940711
ZINC
ZINC000005513458

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0288 mg/mLALOGPS
logP3.65ALOGPS
logP2.83Chemaxon
logS-4.1ALOGPS
pKa (Strongest Acidic)14.51Chemaxon
pKa (Strongest Basic)-1.3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area86.99 Å2Chemaxon
Rotatable Bond Count12Chemaxon
Refractivity109.56 m3·mol-1Chemaxon
Polarizability44.39 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0019000000-f1925edcb6e0fe7268d2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0029000000-284eb0068cbe76b23f6b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0039000000-dc644842faed5c33cfb6
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0532-3669000000-fc54dd91ee29e1d19cbf
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0596-7249000000-2efa8de3284697a02325
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00or-9651000000-114ca1d30317ce7d4964
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-190.54222
predicted
DeepCCS 1.0 (2019)
[M+H]+192.19542
predicted
DeepCCS 1.0 (2019)
[M+Na]+198.35226
predicted
DeepCCS 1.0 (2019)

Drug created at February 25, 2016 18:53 / Updated at February 21, 2021 18:53